Teva faces EU fine for disparaging rival multiple sclerosis medicine, sources say

Teva (TEVA.TA), opens new tab, the world's largest generic drugmaker, will be hit with an EU antitrust fine in the coming weeks for disparaging a rival product to its blockbuster multiple sclerosis medicine Copaxone, people with direct knowledge of the matter said on Tuesday.